Posted by Michael Wonder on 17 May 2021
AffyImmune Therapeutics' AIC100 granted fast track designation for treating thyroid cancer
17 May 2021 - AffyImmune Therapeutics announced today that the US FDA granted fast track designation to its lead compound, AIC100, for the treatment of anaplastic thyroid cancer and refractory poorly differentiated thyroid cancer.
The company previously received orphan drug designation for AIC100.
